These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 6693139)

  • 1. Genetic control of the antibody response to allotypes of murine C4.
    Spinella DG; Roper LA; Passmore HC
    Immunogenetics; 1984; 19(1):87-92. PubMed ID: 6693139
    [No Abstract]   [Full Text] [Related]  

  • 2. A new genetic polymorphism of murine C4 (Ss) proteins: demonstration of antigenically distinguishable allotypes of C4 and their linkage to H-2.
    Natsuume-Sakai S
    Immunobiology; 1980; 158(1-2):10-3. PubMed ID: 7203514
    [No Abstract]   [Full Text] [Related]  

  • 3. Three Chido determinants detected on the B5Rg+ allotype of human C4: their expression in Ch-typed donors and families.
    Giles CM
    Hum Immunol; 1987 Feb; 18(2):111-22. PubMed ID: 2435683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Murine binding protein of the fourth component of complement: structural polymorphism and its linkage to the major histocompatibility complex.
    Kaidoh T; Natsuume-Sakai S; Takahashi M
    Proc Natl Acad Sci U S A; 1981 Jun; 78(6):3794-8. PubMed ID: 6943584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Restriction fragment analysis of H-2 recombinant mouse strains with crossovers between E alpha and C4 genes.
    Lafuse WP; Lee ST; Castle L; David CS
    Immunogenetics; 1989; 30(5):387-9. PubMed ID: 2572548
    [No Abstract]   [Full Text] [Related]  

  • 6. The murine H-2.7 specificity is an antigenic determinant of C4d, a fragment of the fourth component of the complement system.
    Ferreira A; David CS; Nussenzweig V
    J Exp Med; 1980 Jun; 151(6):1424-35. PubMed ID: 6155423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic variation in glycosylation of the fourth component of murine complement. Association with hemolytic activity.
    Karp DR; Atkinson JP; Shreffler DC
    J Biol Chem; 1982 Jul; 257(13):7330-5. PubMed ID: 7085628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. S region genetic control of murine C4 biosynthesis: analysis of pro-C4 cleavage.
    Karp DR; Shreffler DC
    Immunogenetics; 1982; 16(2):171-6. PubMed ID: 6754588
    [No Abstract]   [Full Text] [Related]  

  • 9. Conversion of the C4d.2 serologic allotype of murine complement component C4 to the C4d.1 allotype by site-specific mutagenesis.
    Mathias P; Shreffler DC; Cooper NR; Ogata RT
    J Immunol; 1990 Jan; 144(2):607-9. PubMed ID: 2295802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two monoclonal anti-C4d reagents react with epitopes closely related to Rg:1 and Ch:1.
    Giles CM; Fielder AH; Lord DK; Robson T; O'Neill GJ
    Immunogenetics; 1987; 26(4-5):309-12. PubMed ID: 2443448
    [No Abstract]   [Full Text] [Related]  

  • 11. A newly defined murine alloantigen controlled by the S region of the H-2 complex: molecular association with the fourth component of complement.
    Spinella DG; Passmore HC
    J Immunol; 1983 Feb; 130(2):824-8. PubMed ID: 6184407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antigenic determinants of human C4, Rodgers and Chido.
    Giles CM
    Exp Clin Immunogenet; 1988; 5(2-3):99-114. PubMed ID: 2483343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Duplications of complement and non-complement genes of the H-2S region: evolutionary aspects of the C4 isotypes and molecular analysis of their expression variants.
    Tosi M; Lévi-Strauss M; Georgatsou E; Amor M; Meo T
    Immunol Rev; 1985 Oct; 87():151-83. PubMed ID: 3902621
    [No Abstract]   [Full Text] [Related]  

  • 14. Differential tumor immunogenicity of DBA/2 mouse lymphoma L1210 and its sublines. III. Control of host resistance to drug-resistant L1210 sublines by H-2-linked and non-H-2-linked genes.
    Fuji H; Murakami M
    J Natl Cancer Inst; 1983 Jan; 70(1):119-25. PubMed ID: 6296515
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polymorphism of the human complement component C4.
    Campbell RD; Dunham I; Kendall E; Sargent CA
    Exp Clin Immunogenet; 1990; 7(1):69-84. PubMed ID: 1971760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A monoclonal anti-C4d that demonstrates a specificity related to anti-Ch.
    Giles CM; Ford DS
    Transfusion; 1986; 26(4):370-4. PubMed ID: 3523873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complement allotypes in familial and sporadic Alzheimer's disease.
    Panegyres PK; Dawkins RL
    J Neurol; 1991 Sep; 238(6):325-6. PubMed ID: 1940983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigation of allotypes of HLA class III (C2, BF and C4) in patients with schizophrenia.
    Wang C; Jian BX; Jiang XD; Zhao XZ
    Chin Med J (Engl); 1992 Apr; 105(4):316-8. PubMed ID: 1618015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. C4d DNA sequences of two infrequent human allotypes (C4A13 and C4B12) and the presence of signal sequences enhancing recombination.
    Martínez-Quiles N; Paz-Artal E; Moreno-Pelayo MA; Longás J; Ferre-López S; Rosal M; Arnaiz-Villena A
    J Immunol; 1998 Oct; 161(7):3438-43. PubMed ID: 9759862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The origin of the very variable haemolytic activities of the common human complement component C4 allotypes including C4-A6.
    Dodds AW; Law SK; Porter RR
    EMBO J; 1985 Sep; 4(9):2239-44. PubMed ID: 3852741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.